4,457 AbbVie Inc. $ABBV Shares Acquired by Simplicity Wealth LLC

Simplicity Wealth LLC boosted its position in shares of AbbVie Inc. (NYSE:ABBV) by 5.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 86,139 shares of the company’s stock after acquiring an additional 4,457 shares during the period. AbbVie makes up approximately 0.6% of Simplicity Wealth LLC’s holdings, making the stock its 26th largest holding. Simplicity Wealth LLC’s holdings in AbbVie were worth $22,533,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the company. Madrona Financial Services LLC boosted its stake in AbbVie by 18.0% during the third quarter. Madrona Financial Services LLC now owns 3,063 shares of the company’s stock worth $801,000 after buying an additional 468 shares in the last quarter. Carolina Wealth Advisors LLC increased its holdings in AbbVie by 3.1% in the 3rd quarter. Carolina Wealth Advisors LLC now owns 19,316 shares of the company’s stock valued at $5,053,000 after buying an additional 575 shares during the period. NTV Asset Management LLC raised its stake in shares of AbbVie by 0.4% in the 3rd quarter. NTV Asset Management LLC now owns 35,286 shares of the company’s stock valued at $9,230,000 after buying an additional 142 shares in the last quarter. Sowell Financial Services LLC raised its stake in shares of AbbVie by 9.0% in the 3rd quarter. Sowell Financial Services LLC now owns 48,301 shares of the company’s stock valued at $12,635,000 after buying an additional 3,985 shares in the last quarter. Finally, One Wealth Capital Management LLC raised its stake in shares of AbbVie by 308.3% in the 3rd quarter. One Wealth Capital Management LLC now owns 4,781 shares of the company’s stock valued at $1,251,000 after buying an additional 3,610 shares in the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: The U.S. FDA approved a subcutaneous induction regimen for SKYRIZI in adults with moderately to severely active Crohn’s disease. The on-body injector provides a more convenient administration option throughout treatment, while Phase 3 data showed superior clinical remission and endoscopic response versus placebo with no new safety risks. The approval could strengthen SKYRIZI’s commercial position and support AbbVie’s post-Humira growth strategy. FDA approves subcutaneous SKYRIZI induction for Crohn’s disease
• Positive Sentiment: AbbVie’s dividend remains a key defensive attraction. Analysts and financial commentators point to the company’s ability to maintain shareholder payouts despite Humira’s patent loss, supported by growth from SKYRIZI, RINVOQ and other newer products. AbbVie’s dividend after Humira’s patent cliff
• Neutral Sentiment: AbbVie’s Phase 3 INTREPID trial for lutikizumab in hidradenitis suppurativa met its primary endpoint and eight ranked secondary endpoints, including reduced pain and fewer flares. However, reported efficacy was viewed by some analysts as underwhelming relative to competing treatments, leaving the drug’s eventual commercial opportunity uncertain. AbbVie reports Phase 3 INTREPID results for lutikizumab
• Negative Sentiment: Investors are approaching next week’s earnings report cautiously. Erste Group lowered its 2026 EPS estimate to $13.90 from $14.00, slightly below the roughly $13.94 consensus, while a Zacks preview said AbbVie lacks the usual indicators for a likely earnings beat. With the shares trading near their 52-week high and at a premium valuation, results and guidance may need to be strong to sustain momentum. AbbVie earnings preview

Insider Activity

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the transaction, the executive vice president directly owned 74,430 shares of the company’s stock, valued at $18,607,500. The trade was a 30.53% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.06% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on ABBV. Argus raised their price objective on shares of AbbVie from $250.00 to $270.00 in a report on Tuesday, August 4th. Wells Fargo & Company upped their target price on shares of AbbVie from $295.00 to $300.00 and gave the company an “overweight” rating in a research note on Monday, August 17th. BNP Paribas Exane increased their price target on shares of AbbVie from $218.00 to $247.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 11th. Barclays raised their price target on shares of AbbVie from $300.00 to $325.00 and gave the stock an “overweight” rating in a research note on Wednesday. Finally, Citigroup upped their price objective on AbbVie from $230.00 to $260.00 and gave the company a “neutral” rating in a research note on Wednesday, July 15th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, AbbVie presently has a consensus rating of “Moderate Buy” and an average target price of $279.86.

AbbVie Stock Up 0.0%

Shares of AbbVie stock opened at $285.66 on Monday. The stock has a market capitalization of $504.70 billion, a P/E ratio of 80.69, a price-to-earnings-growth ratio of 1.30 and a beta of 0.24. The company has a 50-day simple moving average of $266.33 and a 200 day simple moving average of $242.01. AbbVie Inc. has a 12-month low of $190.75 and a 12-month high of $291.40.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, beating analysts’ consensus estimates of $3.61 by $0.04. The firm had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The company’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same period in the previous year, the business earned $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, equities analysts anticipate that AbbVie Inc. will post 13.93 earnings per share for the current year.

AbbVie Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be paid a $1.73 dividend. The ex-dividend date is Thursday, October 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.4%. AbbVie’s payout ratio is 195.48%.

AbbVie Profile

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.